12 results about "Blood cholesterol" patented technology

The present invention relates to the technical field of liver-protecting formula compositions, and in particular, to a liver-protecting milk thistle formula composition, and a preparation method thereof. Technical problems: the liver-protecting milk thistle formula composition, and a preparation method thereof are intended to solve the technical problems that most of existing liver-protecting compositions in the prior art are designed for the general liver protection needs of the general population and cannot specifically treat liver damage caused by excessive alcohol intake and liver diseases such as cirrhosis, acute hepatitis, hepatitis, fatty liver, cholangitis, cholelithiasis, psoriasis, and hypercholesterolemia. Technical solution: a liver-protecting milk thistle formula composition, including the following components: silymarin, puerarin, artichoke extract, glutathione, dandelion extract, and GABA. The liver-protecting formula composition has a good therapeutic effect on liver damage caused by excessive alcohol intake, and liver diseases such as cirrhosis, acute hepatitis, hepatitis, fatty liver, cholangitis, cholelithiasis, psoriasis, and hypercholesterolemia.

The present invention relates to a composition comprising a complex extract of Coptis japonica, Phellodendron Chinensis, Scutellaria baicalensis, Gardenia jasminoides, and Rheum palmatum. The composition was confirmed to: reduce the levels of blood cholesterol, blood lipids, and blood LDL-cholesterol in patients with dyslipidemia; reduce systolic blood pressure without affecting diastolic blood pressure and pulse rate in patients with hypertension; reduce the level of pulse wave velocity (PWV), which is an indicator of arteriosclerosis, in patients with atherosclerosis, and inhibit the recurrence rate for up to 5 years in patients with cerebral infarction. Accordingly, the composition is provided as a therapeutic agent for dyslipidemia, hypertension, arteriosclerosis, or cerebral infarction. In particular, the composition is made into an encapsulated form rather than conventional decoctions, to reduce the content of geniposide, which is reported as a side effect component, and thus an optimal composition which maintains efficacy against dyslipidemia and does not cause side effects is provided.

The purpose of the present invention is to provide: a composition for improving a blood cholesterol level; and a method for improving a blood cholesterol level. The present invention relates to a composition for improving a blood cholesterol level in a human body, the composition containing L-ergothioneine or a salt thereof as an active ingredient.

A portable device and method for non-invasive estimation of the level of physiological values such as blood glucose and blood cholesterol, comprising a central processing unit (1) which includes connections to: a signal emitter which emits signals via electrodes in contact with the skin, which, when processed by a bioimpedance microcontroller and said central processing unit (1), provide values such as hydration, body mass index, bone index; a digital optical sensor (4) which allows calculation of the blood oxygen value, heart rate and temperature; and enzymatic sensors (5) which determine the quantity of glucose or lactate; said central processing unit (1) calculating the physiological values on the basis of an automatic learning algorithm that has been trained with a set of clinical history data from a group of patients for whom at least values of bioimpedance, temperature, oxygen and heart rate are available.

The application belongs to the technical field of biological medicine, and provides application of THADA in hyperlipidemia and cardiovascular metabolic diseases. THADA is used as a biomarker or target to prepare reagents for disease prediction, screening or diagnosis, and to prepare drugs for preventing or treating diseases. Inhibition or destruction of THADA function has the purposes of reducing blood cholesterol, low-density lipoprotein cholesterol (LDL-C) and triglyceride levels, not affecting high-density cholesterol levels, reducing liver triglyceride deposition and liver steatosis, and improving atherosclerosis, and the effect is clear and effective and has no adverse reactions. The application provides a new biomarker and treatment target for hyperlipidemia and cardiovascular metabolic diseases, and has good practical application value and wide application prospect.

The application belongs to the technical field of medicine, and discloses a kind of optical compound and its preparation method and application, specifically discloses the enantiomer has different effect.In vitro experiment, enantiomer shows selectivity to target point, S-isomer tends to activate PPARγ, and R-isomer tends to activate FFAR1.In animal model, the efficacy of enantiomer also shows difference, first, two enantiomers can significantly reduce the blood sugar of animal, and significantly improve the insulin resistance of animal.However, in reducing blood triglyceride, the effect of S-isomer is obviously superior to racemate and R-isomer, and in reducing blood cholesterol, the effect of R-isomer is obviously superior to racemate and S-isomer.Therefore, (S)‑1 has important role in preparing blood sugar reducing, triglyceride reducing drug, and (R)‑1 has more significant effect in reducing blood sugar, reducing cholesterol, and has important significance for clinical targeted treatment and application.

The invention discloses mushroom and lucid ganoderma wine and a brewing method thereof.The mushroom and lucid ganoderma wine is prepared from 260-300 kg of rice wine, 430-470 kg of distilled liquor, 6-12 kg of mushrooms, 1-5 kg of lucid ganoderma, 2-7 kg of milkvetch roots, 2-7 kg of Chinese wolfberry fruits, 1-5 kg of mulberries, 6-12 kg of cistanche deserticola and 250-300 kg of cold boiled water according to 1000 kg of finished products. The lentinus edodes and lucid ganoderma wine brewed by the method integrates the effects of various medicinal and edible food materials such as the sticky rice, the lentinus edodes, the lucid ganoderma and the astragalus membranaceus, and has relatively high nutritional and medicinal values; the effects of resisting cancer, enhancing human immunity, tonifying qi, soothing the nerves, relieving cough and asthma, supporting healthy energy, protecting the liver, resisting fatigue, delaying senescence, reducing blood sugar, promoting circulation, expanding blood vessels, reducing blood cholesterol and triglyceride and the like can be achieved.

The application discloses a traditional Chinese medicine composition with lipid-lowering efficacy, Quling Huatu granules and a preparation method thereof, and belongs to the technical field of Chinese patent medicines. The traditional Chinese medicine composition comprises the following components in parts by weight: 5-10 parts of red yeast rice, 10-30 parts of poria cocos, 5-15 parts of atractylodes, 5-15 parts of dried ginger and 5-15 parts of costus. The atractylodes, the poria cocos and the costus in the application can dispel cold, invigorate the spleen, warm the middle and harmonize the stomach, so that the qi of the spleen and stomach runs smoothly. Meanwhile, the Quling Huatu granules contain statin components, can inhibit the synthesis of excessive cholesterol in the body, increase the synthesis of low-density protein receptors, reduce the blood cholesterol and low-density protein cholesterol levels, prevent the further development of cardiovascular diseases, and also do not cause problems such as liver and kidney function damage and gastrointestinal discomfort.

A composition containing a combination of at least one type of fiber and at least one type of probiotic can be orally administered to a subject in an amount effective in modulating the relationship between the target intestinal bacteria and blood cholesterol levels. This method can achieve at least one outcome, which is improvement of blood cholesterol levels, and prevention and / or treatment of cardiovascular, circulatory, endocrine, and / or nervous system conditions and / or diseases.

The present invention relates to a low-sugar gochujang prepared to contain beneficial components through lactic acid bacteria, particularly postbiotics which are dead cells, while preventing the progression of additional fermentation to prevent off-flavors and overflow of contents. More specifically, the invention relates to a method for manufacturing low-sugar gochujang and low-sugar gochujang prepared using the same, wherein a substitute sugar, dietary fiber, and lactic acid bacteria (dead cells) are mixed in a predetermined ratio to maximize the beneficial components of the lactic acid bacteria, thereby enabling the consumption of said beneficial components without loss through the low-sugar gochujang, and which is characterized by the prevention of adult diseases and chronic diseases due to the low-sugar content. By manufacturing a low-sugar gochujang with a structure similar to a fermented jam or fermented spread that maximizes beneficial components and is made with low sugar, the intake of beneficial insoluble dietary fiber is enhanced, while retaining the characteristics of lactic acid bacteria (postbiotics) and preventing the overflow of contents caused by the generation of off-flavor and fermentation gas, thereby activating the immune function of normal human cells to suppress the proliferation and recurrence of cancer cells, reducing blood sugar and blood cholesterol, and improving lipid metabolism to suppress the formation and accumulation of body fat.

The invention discloses a construction method and application of a fetal-derived hypercholesterolemia animal model. The fetal-derived hypercholesteremia animal model is characterized in that 20 mg / kg of aspirin with a clinical dose is given to rodents (such as Kunming mice) through oral intragastric administration in the middle and late pregnancy periods (such as 9-18 pregnancy), and typical hypercholesteremia appears after high-fat diet is given to male filial generations 8-12 weeks after the male filial generations are born. Based on mice exposed by aspirin during pregnancy, ascorbic acid is externally supplemented to maternal bodies during pregnancy, so that the liver cholesterol synthesis function and the blood cholesterol level of offspring can be effectively reduced. Therefore, the established fetal hypercholesterolemia animal model has the characteristics of novelty, reliability and simplicity and convenience in operation, meanwhile, the effect of reversing the susceptibility of offspring hypercholesterolemia by supplementing ascorbic acid to the maternal body is found, and a new thought and a new technology are provided for early prevention and treatment of fetal hypercholesterolemia.

To provide a composition with a blood cholesterol rise inhibitory action dramatically improved.SOLUTION: A composition contains chitosan, and at least one material selected from the group consisting of the following (a)-(b): (a) at least one functional material selected from resveratrol, lycopene, soybean isoflavone, nattokinase, cacao polyphenol, octacosanol, fucoidan and citrulline; (b) at least one plant material selected from leaves of Morinda citrifolia, seeds of Salvia hispanica, fruits of Olea europaea, and seeds of Linum usitatissimum.SELECTED DRAWING: Figure 1